Patent: 7,083,784
✉ Email this page to a colleague
Summary for Patent: 7,083,784
| Title: | Molecules with extended half-lives, compositions and uses thereof |
| Abstract: | The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules. |
| Inventor(s): | Dall\'Acqua; William (Gaithersburg, MD), Johnson; Leslie S. (Germantown, MD), Ward; Elizabeth Sally (Dallas, TX) |
| Assignee: | MedImmune, Inc. (Gaithersburg, MD) |
| Application Number: | 10/020,354 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,083,784
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | For Injection | 103770 | 06/19/1998 | ⤷ Try a Trial | 2020-12-12 |
| Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | Injection | 103770 | 07/23/2004 | ⤷ Try a Trial | 2020-12-12 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
